A Study of SKLB1028 in Subjects With Relapsed/Refractory Acute Myeloid Leukemia
Status:
Unknown status
Trial end date:
2018-01-01
Target enrollment:
Participant gender:
Summary
Patients will receive oral SKLB1028 for 28 days to study the side effects, tolerability and
best dose for treating relapsed or refractory acute myeloid leukemia With FLT3 Mutations.